The prognostic significance of preoperative serum cancer antigen 15-3 levels in endometrial carcinomas

References

1. ↵
   1. Xu F,
   2. Liu F,
   3. Zhao H,
   4. An G,
   5. Feng G

   (2015) Prognostic significance of mucin antigen MUC1 in various human epithelial cancers: A meta-analysis. Medicine (Baltimore) 94:e2286.

   OpenUrlCrossRef
2. ↵
   1. Soper JT,
   2. Berchuck A,
   3. Olt GJ,
   4. Soisson AP,
   5. Clarke-Pearson DL,
   6. Bast RC Jr.

   (1990) Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. Am J Obstet Gynecol 163:1204–1209.

   OpenUrlPubMed
3. ↵
   1. Scambia G,
   2. Gadducci A,
   3. Panici PB,
   4. Foti E,
   5. Ferdeghini M,
   6. Ferrandina G,
   7. et al.

   (1994) Combined use of CA 125 and CA 15-3 in patients with endometrial carcinoma. Gynecol Oncol 54:292–297.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   1. Baser E,
   2. Gungor T,
   3. Togrul C,
   4. Turkoglu O,
   5. Celen S

   (2014) Preoperative prediction of poor prognostic parameters and adjuvant treatment in women with pure endometrioid type endometrial cancer: what is the significance of tumor markers? Eur J Gynaecol Oncol 35:513–518.

   OpenUrl
5. ↵
   1. Li J,
   2. Lin J,
   3. Luo Y,
   4. Kuang M,
   5. Liu Y

   (2015) Multivariate analysis of prognostic biomarkers in surgically treated endometrial cancer. PloS One 10:e0130640.

   OpenUrlPubMed
6. ↵
   1. Hebbar V,
   2. Damera G,
   3. Sachdev GP

   (2005) Differential expression of MUC genes in endometrial and cervical tissues and tumors. BMC Cancer 5:124.

   OpenUrlCrossRefPubMed
7. ↵
   1. Creasman WT,
   2. Odicino F,
   3. Maisonneuve P,
   4. Quinn MA,
   5. Beller U,
   6. Benedet JL,
   7. et al.

   (2006) Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95(Suppl 1):105–143.

   OpenUrlCrossRef
8. ↵
   1. Torre LA,
   2. Bray F,
   3. Siegel RL,
   4. Ferlay J,
   5. Lortet-Tieulent J,
   6. Jemal A

   (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108.

   OpenUrlCrossRefPubMed
9. ↵
   1. Lu KH,
   2. Daniels M

   (2013) Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention. Fam Cancer 12:273–277.

   OpenUrlCrossRefPubMed
10. ↵
    1. Andreano A,
    2. Rechichi G,
    3. Rebora P,
    4. Sironi S,
    5. Valsecchi MG,
    6. Galimberti S

    (2014) MR diffusion imaging for preoperative staging of myometrial invasion in patients with endometrial cancer: a systematic review and meta-analysis. Eur Radiol 24:1327–1338.

    OpenUrl
11. ↵
    1. Kang S,
    2. Nam JH,
    3. Bae DS,
    4. Kim JW,
    5. Kim MH,
    6. Chen X,
    7. et al.

    (2017) Preoperative assessment of lymph node metastasis in endometrial cancer: A Korean Gynecologic Oncology Group study. Cancer 123:263–272.

    OpenUrl
12. ↵
    1. Lo SS,
    2. Cheng DK,
    3. Ng TY,
    4. Wong LC,
    5. Ngan HY

    (1997) Prognostic significance of tumour markers in endometrial cancer. Tumour Biol 18:241–249.

    OpenUrlPubMed
13. ↵
    1. Milam MR,
    2. Java J,
    3. Walker JL,
    4. Metzinger DS,
    5. Parker LP,
    6. Coleman RL,
    7. et al.

    (2012) Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol 119:286–292.

    OpenUrlCrossRefPubMed
14. ↵
    1. Amant F,
    2. Mirza MR,
    3. Koskas M,
    4. Creutzberg CL

    (2015) Cancer of the corpus uteri. Int J Gynaecol Obstet 131:96–104.

    OpenUrlPubMed
15. ↵
    1. Żyła MM,
    2. Wilczyński JR,
    3. Kostrzewa M,
    4. Księżakowska-Łakoma K,
    5. Nowak M,
    6. Stachowiak G,
    7. et al.

    (2016) The significance of markers in the diagnosis of endometrial cancer. Prz Menopauzalny 15:176–185.

    OpenUrl
16. ↵
    1. Cherchi PL,
    2. Dessole S,
    3. Ruiu GA,
    4. Ambrosini G,
    5. Farina M,
    6. Capobianco,
    7. et al.

    (1999) The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma. Eur J Gynaecol Oncol 20:315–317.

    OpenUrlPubMed
17. ↵
    1. Mylonas I,
    2. Mayr D,
    3. Walzel H,
    4. Shabani N,
    5. Dian D,
    6. Kuhn C,
    7. et al.

    (2007) Mucin 1, Thomsen-Friedenreich expression and galectin-1 binding in endometrioid adenocarcinoma: an immunohistochemical analysis. Anticancer Res 27:1975–1980.

    OpenUrlAbstract/FREE Full Text
18. ↵
    1. Berek JS,
    2. Hacker NF

    1. Hacker NF,
    2. Friedlander MY

    (2015) in Berek & Hacker's Gynecologic Oncology, Uterine Cancer, eds Berek JS, Hacker NF (Wolters Kluwer, Philadelphia (PA)), 6th Edition, pp 390–442.
19. ↵
    1. Yildiz A,
    2. Ozcan A,
    3. Yetimalar MH,
    4. Kasap B,
    5. Yigit S,
    6. Kılıc Sakarya D,
    7. et al.

    (2013) The predictability of lymph node metastasis in patients with endometrial cancer. Turkiye Klinikleri J Med Sci 33:1028–1036.

    OpenUrl
20. ↵
    1. Hidaka T,
    2. Nakashima A,
    3. Shima T,
    4. Hasegawa T,
    5. Saito S

    (2010) Systemic lymphadenectomy cannot be recommended for low-risk corpus cancer. Obstet Gynecol Int 2010:490219.

    OpenUrlPubMed
21. ↵
    1. Kokcu A,
    2. Kurtoglu E,
    3. Celik H,
    4. Kefeli M,
    5. Tosun M,
    6. Onal M

    (2015) Is surgical staging necessary for patients with low-risk endometrial cancer?a retrospective clinical analysis. Asian Pac J Cancer Prev 16:5331–5335.

    OpenUrl
22. ↵
    1. Alcazar JL,
    2. Dominguez-Piriz J,
    3. Juez L,
    4. Caparros M,
    5. Jurado M

    (2016) Intraoperative Gross examination and intraoperative frozen section in patients with endometrial cancer for detecting deep myometrial invasion: a systematic review and meta-analysis. Int J Gynecol Cancer 26:407–415.

    OpenUrlAbstract/FREE Full Text